Artiva Biotherapeutics (ARTV) Other Accumulated Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Other Accumulated Expenses for 4 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 25.99% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 25.99% YoY), while the FY2025 annual figure was $73000.0, down 95.04% from the prior year.
• Other Accumulated Expenses rose to $1.1 million in Q1 2026 per ARTV's latest filing, from $73000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.9 million in Q4 2023 and bottomed at $73000.0 in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $1.1 million across 4 years, with a median of $973000.0 in 2025.
• Annual changes were most pronounced in 2025 — Other Accumulated Expenses plunged 95.04% — and 2026, when it increased 25.99%.
• Artiva Biotherapeutics' Other Accumulated Expenses stood at $2.9 million in 2023, then slumped by 48.55% to $1.5 million in 2024, then slumped by 95.04% to $73000.0 in 2025, then soared by 1341.1% to $1.1 million in 2026.
• Business Quant data shows ARTV's Other Accumulated Expenses at $1.1 million in Q1 2026, $73000.0 in Q4 2025, and $442000.0 in Q3 2025.